Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6402683063
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BHCYJ1
NKTR
Nektar Therapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Nektar Therapeutics
ISIN
US6402683063
TICKER
NKTR
MIC
XNAS
REUTERS
NKTR.OQ
BLOOMBERG
NKTR US
Mo., 04.05.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 03.05.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 03.05.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - May 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 02.05.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 02.05.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and 2,950 restricted stock units (RSUs) to six newly-hire...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - May 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-01951, is on behalf of...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 30, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 30.04.2026       Nektar Therapeutics
US6402683063

Wall Street Reassessment: Analyst Opinion Evolution on NKTRNEW YORK, April 30, 2026 /PRNewswire/ -- At least seven major Wall Street firms issued reports on December 16, 2025, each flagging the same problem: four patients who never should have been randomized into Nektar Therapeutics' (NASDAQ: NKTR) pivotal REZOLVE-AA trial were included, and the...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Nekta...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 29, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclu...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Nektar Therapeutics
US6402683063

Executive Accountability: Jonathan Zalevsky Named in Securities ActionNEW YORK, April 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors that Jonathan Zalevsky, Chief Research and Development Officer of Nektar Therapeutics (NASDAQ: NKTR), is named as an individual defendant in a securities class action filed on behalf of shareho...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive, (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern T...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 28, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 27.04.2026       Nektar Therapeutics
US6402683063

BENSALEM, Pa., April 27, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEKTAR THERAPEUTICS (NKTR), CONTAC...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 27.04.2026       Nektar Therapeutics
US6402683063

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025. Nektar describes itself as a “biopharmaceutical company focused on discovering and developing therapies that selectively modul...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 27.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 26.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Nektar Therapeutics
US6402683063

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering,...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, April 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit....
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Nektar Therapeutics
US6402683063

The Red Flags: What Insiders Allegedly Knew Before Shareholders DidNEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Nektar Therapeutics (NASDAQ: NKTR). YOU MAY BE AFFEC...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Nektar Therapeutics
US6402683063

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 22, 2026 /PRNewswire/ -- IMPORTANT DATE: May 5, 2026. Investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares of its common stock. Nektar is selling 3,532,609...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Nektar Therapeutics
US6402683063

Bernstein Liebhard LLP:Do you, or did you, own shares of Nektar Therapeutics (NASDAQ: NKTR)?Did you purchase your shares between February 26, 2025 and December 15, 2025, inclusive?Did you lose money in your investment in Nektar Therapeutics?Do you want to discuss your rights?New York, New York--(Newsfile Corp. - April 21, 2026) - Bernstein Liebhard...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Nektar Therapeutics
US6402683063

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class period listed are encouraged to...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you p...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $250,000,000 of its shares of its common stock and, in lieu of common sto...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Nektar Therapeutics
US6402683063

29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatmentIncreasing proportions of patients achieved clinically meaningful hair growth thresholds across numerous SALT measurements with 94% of patients completing treatment extensionFa...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Nektar Therapeutics
US6402683063

Instrument ID [24281011] (ITH0 - US6402683063) suspended...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Nektar Therapeutics
US6402683063

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholder...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purcha...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Nektar Therapeutics
US6402683063

SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-A...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 19.04.2026       Nektar Therapeutics
US6402683063

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Nektar Therapeutics
US6402683063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Nektar Therapeutics
Charts & Research Termsheets Terminal
Permalink